Reply to the Author

Edward Mpoza¹, David B Meya^{1

2}

Affiliations

Comment

Edward Mpoza et al. Clin Infect Dis. 2021.

. 2021 Nov 2;73(9):e2820.

doi: 10.1093/cid/ciaa1566.

Edward Mpoza¹, David B Meya^{1

2}

No abstract available

Comment on

Cryptococcal Antigenemia in Human Immunodeficiency Virus Antiretroviral Therapy-Experienced Ugandans With Virologic Failure.
Mpoza E, Rajasingham R, Tugume L, Rhein J, Nabaggala MS, Ssewanyana I, Nyegenye W, Kushemererwa GE, Mulema V, Kalamya J, Kiyaga C, Kabanda J, Ssali M, Boulware DR, Meya DB. Mpoza E, et al. Clin Infect Dis. 2020 Oct 23;71(7):1726-1731. doi: 10.1093/cid/ciz1069. Clin Infect Dis. 2020. PMID: 31679007 Free PMC article.
Cryptococcal Antigenemia and the Implications of Viral Load-Directed Cryptococcal Antigen Screening in Antiretroviral Therapy-Experienced Patients With Human Immunodeficiency Virus.
Paulin HN, Raizes E. Paulin HN, et al. Clin Infect Dis. 2021 Nov 2;73(9):e2819-e2820. doi: 10.1093/cid/ciaa1565. Clin Infect Dis. 2021. PMID: 33069168 Free PMC article. No abstract available.

1. Meya DB, Manabe YC, Castelnuovo B, et al. . Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis 2010; 51:448–55. - PMC - PubMed
1. Jarvis JN, Harrison TS, Lawn SD, Meintjes G, Wood R, Cleary S. Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLoS One 2013; 8:e69288. - PMC - PubMed